Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "L01F" (26)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Rituximab (L01FA01) 2 products
WHO-DDD
Ituxredi 500 mg/ 50 ml
k.A.
Concentrate for infusion: Rituximabum 500mg / 50ml
Dr. Reddy's
Laboratories SA
A
FB
G
Ituxredi 100 mg/ 10 ml
2
k.A.
Concentrate for infusion: Rituximabum 100mg / 10ml
Dr. Reddy's
Laboratories SA
A
FB
G
Obinutuzumab (L01FA03) 1 products
WHO-DDD
L
IP
Gazyvaro 1000 mg/40 ml
Durchstechflasche(n)
3045.01
3328.05
10 %
Concentrate for infusion: Obinutuzumabum 1000mg / 40ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
Trastuzumab (L01FD01) 5 products
WHO-DDD
L
IP
PP
Herceptin subkutan
600mg/5ml
1484.04
1630.40
10 %
Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
L
IP
Ogivri 150 mg
456.84
513.25
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg
Medius AG
A / SL
FB
G
L
IP
Ogivri 440 mg
1335.64
1469.00
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 440 mg
Medius AG
A / SL
FB
G
L
IP
Herzuma 150 mg
456.84
513.25
10 %
poudre pour solution à diluer pour perfusion: Trastuzumabum 150 mg
iQone Healthcare
Switzerland SA
A / SL
FB
G
L
IP
Herzuma 440 mg
1335.64
1469.00
10 %
poudre pour solution à diluer pour perfusion: Trastuzumabum 440 mg
iQone Healthcare
Switzerland SA
A / SL
FB
G
Panitumumab (L01FE02) 2 products
WHO-DDD
L
IP
Vectibix 100 mg/5 ml
Durchstechflasche(n)
377.45
426.90
10 %
Concentrate for infusion: Panitumumabum 100mg / 5ml
Amgen Switzerland AG
A / SL
FB
G
L
IP
Vectibix 400 mg/20 ml
Durchstechflasche(n)
1509.81
1658.40
10 %
Concentrate for infusion: Panitumumabum 400mg / 20ml
Amgen Switzerland AG
A / SL
FB
G
Nivolumab (L01FF01) 1 products
WHO-DDD
Opdivo subkutan 600 mg/5 ml
k.A.
Injection solution: Nivolumabum 600mg / 5ml
Bristol-Myers Squibb SA
A
FB
G
Pembrolizumab (L01FF02) 1 products
WHO-DDD
L
IP
Keytruda 100 mg/4 ml
2
3933.27
4294.10
10 %
Concentrate for infusion: Pembrolizumabum 100mg / 4ml
MSD Merck Sharp &
Dohme AG
A / SL
FB
G
Serplulimab (L01FF12) 1 products
WHO-DDD
Hetronifly 100 mg/10 ml
k.A.
Concentrate for infusion: Serplulimabum 100mg / 10ml
Accord Healthcare AG
A
FB
G
Bevacizumab (L01FG01) 4 products
WHO-DDD
L
IP
Abevmy 100 mg/4 ml
223.22
261.30
10 %
Concentrate for infusion: Bevacizumabum 100mg / 4ml
Medius AG
A / SL
FB
G
L
IP
Abevmy 400 mg/16 ml
834.46
931.85
10 %
Concentrate for infusion: Bevacizumabum 400mg / 16ml
Medius AG
A / SL
FB
G
L
IP
Vegzelma 100 mg/4 ml
257.57
296.55
10 %
Concentrate for infusion: Bevacizumabum 100mg / 4ml
iQone Healthcare
Switzerland SA
A / SL
FB
G
L
IP
Vegzelma 400 mg/16 ml
962.84
1063.55
10 %
Concentrate for infusion: Bevacizumabum 400mg / 16ml
iQone Healthcare
Switzerland SA
A / SL
FB
G
Gemtuzumab Ozogamicin (L01FX02) 1 products
WHO-DDD
IP
Mylotarg 5 mg
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg
Pfizer AG
A
FB
G
Mogamulizumab (L01FX09) 1 products
WHO-DDD
L
IP
Poteligeo 4 mg/ml
1302.65
1433.15
10 %
Concentrate for infusion: Mogamulizumabum 20 mg
Kyowa Kirin Sàrl
A / SL
FB
G
Sacituzumab Govitecan (L01FX17) 1 products
WHO-DDD
L
IP
TRODELVY 180 mg
924.25
1021.60
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Sacituzumabum Govitecanum 180 mg
Gilead Sciences
Switzerland Sàrl
A / SL
FB
G
Amivantamab (L01FX18) 2 products
WHO-DDD
IP
Rybrevant SC 1600 mg/10 ml
k.A.
Injection solution: Amivantamabum 1600mg / 10ml
Janssen-Cilag AG
A
FB
G
IP
Rybrevant SC 2240 mg/14 ml
k.A.
Injection solution: Amivantamabum 2240mg / 14ml
Janssen-Cilag AG
A
FB
G
Mirvetuximab Soravtansine (L01FX26) 1 products
WHO-DDD
L
IP
ELAHERE 100 mg/20 ml
3106.01
3394.40
10 %
Concentrate for infusion: Mirvetuximabum Soravtansinum 100mg / 20ml
AbbVie AG
A / SL
FB
G
Zolbetuximab (L01FX31) 3 products
WHO-DDD
IP
Vyloy 100 mg
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Zolbetuximabum 100 mg
Astellas Pharma AG
A
FB
G
IP
Vyloy 100 mg
3
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Zolbetuximabum 100 mg
Astellas Pharma AG
A
FB
G
IP
Vyloy 300 mg
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Zolbetuximabum 300 mg
Astellas Pharma AG
A
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home
